Effect of nafronyl on lactate and pyruvate in the cerebrospinal fluid of patients with senile dementia.
In a single-blind study, 12 men (mean age 63 years) with senile dementia were given nafronyl in a dosage of 100 mg eight times daily for a week, followed by 100 mg four times daily for 12 weeks. Rigorous clinical, laboratory and psychometric assessments revealed no toxicity and no significant effects on vital functions. In the cerebrospinal fluid, the ratio of lactate to pyruvate decreased--a finding consistent with an increase in the aerobic metabolism of glucose.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000134:cerebrospinal fluid; D000368:Aged; D003704:Dementia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D005663:Furans / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007773:Lactates / Q000134:cerebrospinal fluid*; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D009257:Nafronyl / Q000494:pharmacology* / Q000627:therapeutic use; D011773:Pyruvates / Q000134:cerebrospinal fluid*
D005663:Furans; D007773:Lactates; D011773:Pyruvates; D015102:3,4-Dihydroxyphenylacetic Acid; D009257:Nafronyl; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D005947:Glucose; D006719:Homovanillic Acid